Table 1.
Characteristics of Ab-Positive (Ab+) TrialNet Participants
| Ab+ Subjects Without T1D (N = 732) | Ab+ Subjects Who Progressed to T1D (N = 284) | P Valuea | |
|---|---|---|---|
| Age at initial Ab+, median (IQR) | 12.4 (7.2 to 31.7) | 9.7 (6.0 to 14.7) | <0.001 |
| Follow-up, median (IQR)b | 5.1 (3.1 to 7.2) | 2.6 (1.5 to 4.5) | <0.001 |
| Sex: male, N (%) | 351 (48) | 152 (54) | 0.02 |
| AUC glucose at first OGTT (mg/dL), mean (SD) | 2353 (298) | 2648 (408) | <0.001 |
| Relationship to proband, N (%) | <0.001 | ||
| Sibling | 376 (51) | 166 (59) | |
| Parent | 150 (21) | 28 (10) | |
| Offspring | 149 (20) | 69 (24) | |
| Other/unknown | 57 (8) | 21 (7) | |
| HLA genotypes, N (%) | <0.001 | ||
| HLA-DR3/3 | 35 (5) | 14 (5) | |
| HLA-DR3/4 | 107 (15) | 78 (27) | |
| HLA-DR3/Xc | 116 (16) | 33 (12) | |
| HLA-DR4/4 | 61 (8) | 28 (10) | |
| HLA-DR4/Xc | 221 (30) | 84 (29) | |
| Other/unavailable | 192 (26) | 47 (17) |
Abbreviation: IQR, interquartile range.
a
Wilcoxon test for comparing medians; χ2 for proportions between two groups.
b
Follow-up: time to diabetes or last visit for those who did not develop diabetes.
c
Where X equals not DR3, not DR4. HLA DR X/X (i.e., not 3/3, 3/4, 3/X, 4/4, or 4/X) is used as reference group.